EcoR1 Capital’s Seres Therapeutics MCRB Stock Holding History

EcoR1 Capital’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-2,000	Closed	-$1.66M	–	26
2015 Q2	$1.66M	Buy	+2,000	New	+$1.75M	0.55%	21

Other funds holding MCRB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FV2GP

Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

EcoR1 Capital's MCRB Position: Q3 2015 in Review

EcoR1 Capital sold out of Seres Therapeutics (MCRB) in Q3 2015, closing a stake of 2,000 shares — an estimated $1.66M sold.

EcoR1 Capital first reported a position in MCRB in Q2 2015 and held it in 1 quarter. The position peaked at $1.66M in Q2 2015. 60 funds tracked by Wall St. Rank hold MCRB as of Q3 2015.

EcoR1 Capital reported no remaining Seres Therapeutics position as of Q3 2015 after selling out during the quarter.
EcoR1 Capital sold 2,000 Seres Therapeutics shares in Q3 2015, an estimated $1.66M.
EcoR1 Capital first reported a position in Seres Therapeutics in Q2 2015 and held it in 1 quarter.
EcoR1 Capital's Seres Therapeutics position peaked at $1.66M in Q2 2015.
60 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2015.

Based on EcoR1 Capital's 13F filing for Q3 2015, filed 16 Nov 2015.